Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia

一项针对B系急性淋巴细胞白血病微小残留病灶患者的blinatumomab II期研究显示，长期无复发生存期较长。